From GlobeNewswire: 2025-05-09 00:25:00

Zealand Pharma has finalized a collaboration and license agreement with Roche, meeting all closing conditions, including regulatory requirements. This partnership aims to address obesity management by leveraging Zealand Pharma’s expertise in peptide-based medicines. The agreement signifies a significant step towards achieving the company’s vision. Zealand Pharma, headquartered in Copenhagen, Denmark, focuses on developing innovative drug candidates, with multiple products in clinical development and on the market. This collaboration with Roche is expected to unlock the full potential of petrelintide for individuals struggling with weight issues.



Read more at GlobeNewswire: Zealand Pharma announces closing of collaboration and